GW Pharmaceuticals (NASDAQ:GWPH) got some positive marijuana news from the U.S. Food and Drug Administration (FDA) on Monday.
The good marijuana news for GWPH is that the organization is giving its approval to Epidiolex. This is a type of oral solution for the treatment of seizures. This includes seizures from two types of rare epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.
This bit of marijuana news marks the first time in the history of the U.S. that the FDA has given its approval to a purified drug derived from marijuana. However, customers with concerns about psychoactive effects from the drug need not worry.
Epidiolex won’t be causing psychoactive effects comparable to marijuana. That’s because it doesn’t contain tetrahydrocannabinol (THC). THC is the active ingredient in marijuana that causes the “high” that users experience. Instead, patients are taking cannabidiol (CBD), which is another component of the drug.
The FDA notes that the current Controlled Substances Act requires Epidiolex be listed as a Schedule I substance due to its connection to marijuana. However, it has looked over the abuse potential of the drug and is advising the Drug Enforcement Administration on how to handle the situation.
The effects of Epidiolex could very well be a boon to patients with the two forms of epilepsy mentioned above. The drug went through three randomized, double-blind, placebo-controlled clinical trials to determine its effectiveness in treating the two diseases. It was shown to be more effective at reducing seizures, when taken with other drugs, than a placebo during these studies.
Despite all this good marijuana news, there are still some negative side effects to Epidiolex. These side effects are “sleepiness, sedation and lethargy; elevated liver enzymes; decreased appetite; diarrhea; rash; fatigue, malaise and weakness; insomnia, sleep disorder and poor quality sleep; and infections.”
As of this writing, William White did not hold a position in any of the aforementioned securities.